Hikma Pharmaceuticals Plc Director/PDMR Shareholding (4388C)
April 13 2017 - 2:43AM
UK Regulatory
TIDMHIK
RNS Number : 4388C
Hikma Pharmaceuticals Plc
13 April 2017
Hikma Pharmaceuticals PLC - EIP Awards
LONDON, 13 April 2017: Hikma Pharmaceuticals PLC (LSE: HIK)
(NasdaqDubai: HIK) announces that the Remuneration Committee has
made the following conditional awards and nil cost options under
the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the
"EIP") to Persons Discharging Managerial Responsibility ("PDMR") of
the Company.
Awards under the EIP were made on 13 April 2017 at a price of
1,740 pence per Ordinary Share (being the average price for the
30-day period prior to 31 December 2016, in accordance with the EIP
rules) as follows:
Notification and public disclosure of transactions by persons
discharging managerial responsibilities
1 Details of the person discharging managerial responsibilities
/ person closely associated
--- --------------------------------------------------------------------------
a) Name Majda Labadi
--- ------------------------ ------------------------------------------------
2 Reason for the notification
--- --------------------------------------------------------------------------
a) Position/status Corporate Vice President for Human Resources
and Head of Operations, MENA
--- ------------------------ ------------------------------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------ ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--- --------------------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- ------------------------ ------------------------------------------------
b) LEI 549300BNS685UXH4JI75
--- ------------------------ ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--- --------------------------------------------------------------------------
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
--- ------------------------ ------------------------------------------------
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element B of the 2014 Executive Incentive Plan
(EIP). Shares under Element B EIP award will
vest after 2 years.
--- ------------------------ ------------------------------------------------
c) Price(s) and Price(s): GBP17.40
volume(s) Volume(s): 17,825
--- ------------------------ ------------------------------------------------
d) Aggregated information N/A
--- ------------------------ ------------------------------------------------
e) Date of the transaction 13 April 2017
--- ------------------------ ------------------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- ------------------------ ------------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
--- --------------------------------------------------------------------------
a) Name Majda Labadi
--- ------------------------ ------------------------------------------------
2 Reason for the notification
--- --------------------------------------------------------------------------
a) Position/status Corporate Vice President for Human Resources
and Head of Operations, MENA
--- ------------------------ ------------------------------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------ ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--- --------------------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- ------------------------ ------------------------------------------------
b) LEI 549300BNS685UXH4JI75
--- ------------------------ ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--- --------------------------------------------------------------------------
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
--- ------------------------ ------------------------------------------------
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element C of the 2014 Executive Incentive Plan
(EIP). Shares under Element C EIP award will
vest after 3 years.
--- ------------------------ ------------------------------------------------
c) Price(s) and Price(s): GBP17.40
volume(s) Volume(s): 16,146
--- ------------------------ ------------------------------------------------
d) Aggregated information N/A
--- ------------------------ ------------------------------------------------
e) Date of the transaction 13 April 2017
--- ------------------------ ------------------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- ------------------------ ------------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
--- -----------------------------------------------------------------------------
a) Name Susan Ringdal
--- ------------------------ ---------------------------------------------------
2 Reason for the notification
--- -----------------------------------------------------------------------------
a) Position/status Vice President, Corporate Strategy and Investor
Relations
--- ------------------------ ---------------------------------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--- -----------------------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- ------------------------ ---------------------------------------------------
b) LEI 549300BNS685UXH4JI75
--- ------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--- -----------------------------------------------------------------------------
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
--- ------------------------ ---------------------------------------------------
b) Nature of the The Company granted the named individual above
transaction a nil cost option to acquire Shares under Element
B of the 2014 Executive Incentive Plan (EIP).
Shares under Element B EIP award will vest after
2 years.
--- ------------------------ ---------------------------------------------------
c) Price(s) and Price(s): GBP17.40
volume(s) Volume(s): 14,031
--- ------------------------ ---------------------------------------------------
d) Aggregated information N/A
--- ------------------------ ---------------------------------------------------
e) Date of the transaction 13 April 2017
--- ------------------------ ---------------------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- ------------------------ ---------------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
--- -----------------------------------------------------------------------------
a) Name Susan Ringdal
--- ------------------------ ---------------------------------------------------
2 Reason for the notification
--- -----------------------------------------------------------------------------
a) Position/status Vice President, Corporate Strategy and Investor
Relations
--- ------------------------ ---------------------------------------------------
b) Initial notification Initial notification
/Amendment
--- ------------------------ ---------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--- -----------------------------------------------------------------------------
a) Name Hikma Pharmaceuticals PLC
--- ------------------------ ---------------------------------------------------
b) LEI 549300BNS685UXH4JI75
--- ------------------------ ---------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--- -----------------------------------------------------------------------------
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
--- ------------------------ ---------------------------------------------------
b) Nature of the The Company granted the named individual above
transaction a nil cost option to acquire Shares under Element
C of the 2014 Executive Incentive Plan (EIP).
Shares under Element C EIP award will vest after
3 years.
--- ------------------------ ---------------------------------------------------
c) Price(s) and Price(s): GBP17.40
volume(s) Volume(s): 13,477
--- ------------------------ ---------------------------------------------------
d) Aggregated information N/A
--- ------------------------ ---------------------------------------------------
e) Date of the transaction 13 April 2017
--- ------------------------ ---------------------------------------------------
f) Place of the London Stock Exchange (XLON)
transaction
--- ------------------------ ---------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHGRGDSBSBBGRX
(END) Dow Jones Newswires
April 13, 2017 03:43 ET (07:43 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024
